The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A

Drug Metabolism and Disposition

Volumn 24, Issue 5, 1996, Pages 555-559

  Manchee, Gary R ^a   Eddershaw, Peter J ^a   Ranshaw, Lisa E ^a   Herriott, Deborah ^a   Park, Gilbert R ^b   Bayliss, Martin K ^a   Tarbit, Michael H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYSALMETEROL; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; BUFURALOL; CHLORZOXAZONE; CYTOCHROME P450; DISULFIRAM; DRUG METABOLITE; ETHOXYRESORUFIN; FURAFYLLINE; GR 127433; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SALMETEROL XINAFOATE; SULFAPHENAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; DOSE RESPONSE; DRUG OXIDATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DISULFIRAM; HUMANS; ISOENZYMES; KETOCONAZOLE; MICROSOMES, LIVER; MIDAZOLAM; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; QUINIDINE; RECOMBINANT PROTEINS; SULFAPHENAZOLE; THEOPHYLLINE;

EID: 0029960236     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. R. N. Brogden and D. Faulds: Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42, 895-912 (1991).
2. M. Johnson: Salmeterol: a novel drug for the treatment of asthma. Agents Actions 34, (Suppl.) 79-95 (1991).
3. G. R. Manchee, A. Barrow, S. Kulkarni, E. Palmer, J. Oxford, P. V. Colthup, J. G. Maconochie, and M. H. Tarbit: Disposition of salmeterol xinafoate: a new inhaled bronchodilator in laboratory animals and humans. Drug Metab. Dispos. 21, 1022-1028 (1993).
4. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-157 (1995).
5. F. P. Guengerich, K. Doug-Hyen, and I. Masahiko: Role of human cytochrome P450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
6. D. J. Burkitt, P. I. Mackenzie, M. E. Veronese, and J. O. Miners: In vitro approaches can predict human drug metabolism. Trends Pharmacol. Sci. 14, 292-294 (1993).
7. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25, 261-270 (1995).
8. M. M. Bradford: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248 (1976).
9. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378 (1964).
10. C. A. Lee, S. H. Kadwell, T. A. Kost, and C. J. Serabjit-Singh: CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch. Biochem. Biophys. 319, 157-167 (1995).
11. M. D. Burke and R. T. Mayer: Ethoxyresorufin: direct fluorimetric assay of a microsomal o-dealkylation which is preferentially induced by 3-methylcholanthrene. Drug Metab. Dispos. 2, 583-588 (1974).
12. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Burkittt: Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37, 1137-1144 (1988).
13. K. Chiba, K. Manabe, K. Kobayashi, Y. Takayama, M. Tani, and T. Ishizaki: Development and preliminary application of a simple assay of S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Eur. J. Clin. Pharmacol. 44, 559-562 (1993).
14. T. Kronbach, D. Mathys, J. Gut, T. Catin, and U. A. Meyer: High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxlase and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162, 24-32 (1987).
15. D. Lucas, F. Berthou, C. Girre, F. Poitrenaud, and J.-F. Ménez: High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone is serum: a tool for indirect evaluation of P4502E1 activity in humans. J. Chromatogr. 266, 79-86 (1993).
16. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P4503A4. Mol. Pharmacol. 36, 89-96 (1989).
17. G. Fabre, B. Julian, B. Saint-Aubert, H. Joyeux, and Y. Berger: Evidence for CYP3A-mediated N-deethylation of amiodarone in human microsomal fractions. Drug Metab. Dispos. 21, 978-985 (1993).
18. C.-H. Yun, R. A. Okerholm, and F. P. Guengerich: Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P4503A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21, 403-409 (1993).
19. C.-H. Yun, M. Wood, A. J. J. Wood, and F. P. Guengerich: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. Anesthesiology 77, 467-474 (1992).
20. D. A. Smith and B. C. Jones: Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44, 2089-2098 (1992).